Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2-metastatic breast cancer: A machine learning approach

被引：0
作者：
Moiso, Enrico [1 ]
Ferraro, Emanuela [1 ]
Cabel, Luc [1 ]
Safonov, Anton [1 ]
Ahmed, Mehnaj [1 ]
An, Julia Ah-Reum [1 ]
Jhaveri, Komal L. [1 ]
Norton, Larry [1 ]
Robson, Mark E. [1 ]
Modi, Shanu [1 ]
Chandarlapaty, Sarat [1 ]
Razavi, Pedram [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1074
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2-advanced breast cancer
    Corona, Silvia Paola
    Generali, Daniele
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 321 - 330
  • [42] Cellular senescence in the response of HR+ breast cancer to radiotherapy and CDK4/6 inhibitors
    Vanessa Klapp
    Aitziber Buqué
    Norma Bloy
    Ai Sato
    Takahiro Yamazaki
    Xi Kathy Zhou
    Silvia C. Formenti
    Lorenzo Galluzzi
    Giulia Petroni
    Journal of Translational Medicine, 21
  • [43] The educational impact of a curriculum for oncologists on the latest developments in the use of CDK4/6 inhibitors in HR+/HER2-early and metastatic breast cancer
    Dorkhom, N.
    Ragoonath-Cameron, D.
    Bahra, S.
    Patel, U.
    Phoenix, V.
    ANNALS OF ONCOLOGY, 2022, 33 : S159 - S160
  • [44] Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2– metastatic breast cancer in the United States
    Ravi K. Goyal
    Holly M. Holmes
    Hua Chen
    Susan Abughosh
    Sean D. Candrilli
    Michael L. Johnson
    Breast Cancer Research and Treatment, 2023, 198 : 159 - 166
  • [45] Therapy of HR+/HER2-advanced Breast Cancer CDK4/6 Inhibitors: Studies, Everyday Healthcare and Guidelines
    Ruedesheim, Sabine M.
    BREAST CARE, 2021, 16 (03)
  • [46] Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2-breast cancer: an umbrella review
    Pu, Dongqing
    Xu, Debo
    Wu, Yue
    Chen, Hanhan
    Shi, Guangxi
    Feng, Dandan
    Zhang, Mengdi
    Liu, Zhiyong
    Li, Jingwei
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (01)
  • [47] Should CDK4/6 inhibitors replace chemotherapy in HR+ /HER2− metastatic breast cancer with visceral crisis? Evaluating the emerging evidence
    Armando Orlandi
    Discover Oncology, 16 (1)
  • [48] CDK4/6 inhibitors in advanced HR+/HER2-breast cancer - a multicenter real world data analysis
    Mueller, C.
    Kiver, V
    Solomayer, E-F
    Wagenpfeil, G.
    Neeb, C.
    Blohmer, J. U.
    Abramian, A., V
    Maass, N.
    Schuetz, F.
    Kolberg-Liedtke, C.
    Ralser, D. J.
    Rambow, A-C
    BREAST CARE, 2023, 18 (01) : 31 - 41
  • [49] BPI-16350, a novel promising CDK4/6 inhibitor for HR+/HER2-metastatic breast cancer (MBC): Results from a phase I study
    Zhang, Jian
    Liu, Rujiao
    Gao, Shuiping
    Chen, Wenyan
    Han, Xinghua
    Ma, Yanjie
    Ding, Lieming
    Wang, Jiabing
    Lan, Hong
    Hu, Xichun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2-advanced or metastatic breast cancer in China
    Jia, Caifeng
    Zhang, Sen
    Wang, Jie
    Feng, Bing
    Shi, Fenghao
    Wang, Meiqi
    Li, Sainan
    Xu, Hao
    Wang, Mingxia
    SCIENTIFIC REPORTS, 2025, 15 (01):
12345